Rafarma Pharmaceuticals Market Capitalization vs. Current Liabilities
| RAFA Stock | USD 0.14 0.02 16.67% |
For Rafarma Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rafarma Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rafarma Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rafarma Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rafarma Pharmaceuticals over time as well as its relative position and ranking within its peers.
Rafarma |
Rafarma Pharmaceuticals Current Liabilities vs. Market Capitalization Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Rafarma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rafarma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Rafarma Pharmaceuticals is currently regarded as top stock in market capitalization category among its peers. It also is currently regarded as top stock in current liabilities category among its peers . The ratio of Market Capitalization to Current Liabilities for Rafarma Pharmaceuticals is about 377.69 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Rafarma Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rafarma Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Rafarma Market Capitalization vs. Competition
Rafarma Pharmaceuticals is currently regarded as top stock in market capitalization category among its peers. Market capitalization of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 135.2 Million. Rafarma Pharmaceuticals totals roughly 110.29 Million in market capitalization claiming about 82% of equities under Drug Manufacturers—Specialty & Generic industry.
Rafarma Current Liabilities vs. Market Capitalization
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Rafarma Pharmaceuticals |
| = | 110.29 M |
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Rafarma Pharmaceuticals |
| = | 292 K |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Rafarma Current Liabilities Comparison
Rafarma Pharmaceuticals is currently under evaluation in current liabilities category among its peers.
Rafarma Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Rafarma Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rafarma Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Rafarma Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Rafarma Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Rafarma Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Rafarma Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rafarma Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rafarma Pharmaceuticals' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Rafarma Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Use Investing Themes to Complement your Rafarma Pharmaceuticals position
In addition to having Rafarma Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Thematic Idea Now
Healthcare
Companies that provide healthcare goods and services including hospitals, health maintenance organizations, HMOs, or medical aid manufacturers. The Healthcare theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Rafarma Pink Sheet
To fully project Rafarma Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rafarma Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rafarma Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.